A physician-guided program for FDA-approved GLP-1 treatment — semaglutide (Wegovy®, Rybelsus®) or tirzepatide (Zepbound®). Your Valura Medical clinician evaluates which is appropriate, prescribes through the manufacturer's self-pay program (LillyDirect / NovoCare) or your pharmacy, and monitors your progress monthly. Program fee covers clinical services; medication is billed separately at manufacturer self-pay pricing.
Complete the health questionnaire at checkout. A licensed Valura Medical physician reviews it — usually within 24 hours — and if GLP-1 treatment is appropriate, prescribes branded semaglutide or tirzepatide through the manufacturer's self-pay program or a pharmacy, then monitors you monthly with dose titration and side-effect management. Not appropriate? Full refund.
Compounded GLP-1 copies were a shortage-era workaround. The FDA declared those shortages resolved, which made mass-produced copies of the branded drugs unlawful to compound — and the companies still selling them are the ones receiving FDA letters and manufacturer lawsuits. We prescribe the real, FDA-approved medicines through legitimate channels, where manufacturer self-pay programs have brought cash prices down substantially. Slower-fashionable, faster-safe.
GLP-1 medicines are not appropriate for everyone, including people with a personal/family history of medullary thyroid carcinoma or MEN 2, or a history of pancreatitis. Common side effects include nausea and GI upset, particularly during titration. Your clinician will review full safety information.